# Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis

> **NCT02479802** · PHASE2 · COMPLETED · sponsor: **Instituto Grifols, S.A.** · enrollment: 13 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** Albumin

## Key facts

- **NCT ID:** NCT02479802
- **Lead sponsor:** Instituto Grifols, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02479802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02479802, "Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02479802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*